JP7153662B2 - 薬理学的に活性な脂環式置換ピラゾロ[1,5-a]ピリミジン誘導体 - Google Patents

薬理学的に活性な脂環式置換ピラゾロ[1,5-a]ピリミジン誘導体 Download PDF

Info

Publication number
JP7153662B2
JP7153662B2 JP2019549366A JP2019549366A JP7153662B2 JP 7153662 B2 JP7153662 B2 JP 7153662B2 JP 2019549366 A JP2019549366 A JP 2019549366A JP 2019549366 A JP2019549366 A JP 2019549366A JP 7153662 B2 JP7153662 B2 JP 7153662B2
Authority
JP
Japan
Prior art keywords
formula
carboxylic acid
methyl
derivative
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019549366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510041A (ja
JP2020510041A5 (enExample
Inventor
ボルザ、イシュトバーン
ロマーン、ヴィクトル
エーレシュ、ヤーノシュ
ハダディ、ジュジャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of JP2020510041A publication Critical patent/JP2020510041A/ja
Publication of JP2020510041A5 publication Critical patent/JP2020510041A5/ja
Application granted granted Critical
Publication of JP7153662B2 publication Critical patent/JP7153662B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • C07D491/147Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019549366A 2017-03-13 2018-03-12 薬理学的に活性な脂環式置換ピラゾロ[1,5-a]ピリミジン誘導体 Active JP7153662B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1700108 2017-03-13
HU1700108A HU231058B1 (hu) 2017-03-13 2017-03-13 Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
PCT/IB2018/051599 WO2018167630A1 (en) 2017-03-13 2018-03-12 PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES

Publications (3)

Publication Number Publication Date
JP2020510041A JP2020510041A (ja) 2020-04-02
JP2020510041A5 JP2020510041A5 (enExample) 2021-02-12
JP7153662B2 true JP7153662B2 (ja) 2022-10-14

Family

ID=89992389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019549366A Active JP7153662B2 (ja) 2017-03-13 2018-03-12 薬理学的に活性な脂環式置換ピラゾロ[1,5-a]ピリミジン誘導体

Country Status (32)

Country Link
US (1) US11026946B2 (enExample)
EP (1) EP3596080B1 (enExample)
JP (1) JP7153662B2 (enExample)
KR (1) KR20190127779A (enExample)
CN (1) CN110431142A (enExample)
AR (1) AR111176A1 (enExample)
AU (1) AU2018235266B2 (enExample)
BR (1) BR112019018843A2 (enExample)
CA (1) CA3056185A1 (enExample)
CL (1) CL2019002601A1 (enExample)
CO (1) CO2019010120A2 (enExample)
CY (1) CY1124708T1 (enExample)
DK (1) DK3596080T3 (enExample)
EA (1) EA038756B1 (enExample)
EC (1) ECSP19072975A (enExample)
ES (1) ES2893824T3 (enExample)
GE (1) GEP20217256B (enExample)
HR (1) HRP20211850T1 (enExample)
HU (2) HU231058B1 (enExample)
IL (1) IL268923A (enExample)
LT (1) LT3596080T (enExample)
MX (1) MX2019011000A (enExample)
MY (1) MY195262A (enExample)
PE (1) PE20191646A1 (enExample)
PH (1) PH12019501968A1 (enExample)
PL (1) PL3596080T3 (enExample)
PT (1) PT3596080T (enExample)
RS (1) RS62533B1 (enExample)
SG (1) SG11201907864YA (enExample)
SI (1) SI3596080T1 (enExample)
UA (1) UA124783C2 (enExample)
WO (1) WO2018167630A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
EP4424683A3 (en) 2017-03-13 2024-11-06 Lundbeck La Jolla Research Center, Inc. Dual magl and faah inhibitors
PE20221836A1 (es) 2020-03-26 2022-11-29 Richter Gedeon Nyrt Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa 5
WO2022029666A1 (en) 2020-08-05 2022-02-10 Richter Gedeon Nyrt. PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN115872095A (zh) * 2022-11-28 2023-03-31 南通三鑫车灯配件有限公司 一种汽车车灯反光罩的生产线流转装置

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139240A1 (en) 2006-05-25 2007-12-06 Korea Research Institute Of Chemical Technology 7-(3,4-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidine compounds, process for preparing thereof, and pharmaceutical composition for treating or preventing asthma, chronic obstructive pulmonary disease, arthritis, atopic dermatitis, tumor and degenerative brain diseases comprising the same
JP2011517458A (ja) 2008-03-31 2011-06-09 武田薬品工業株式会社 アポトーシスシグナル調節キナーゼ1阻害剤
US20160304527A1 (en) 2015-04-20 2016-10-20 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2290885T3 (es) 2004-03-02 2008-02-16 F. Hoffmann-La Roche Ag Derivados de 4-(sulfanil-pirimidin-4-ilmetil)-morfolina y compuestos afines como ligandos para el receptor gaba para el tratamiento de la ansiedad, depresion y epilepsia.
GB0512844D0 (en) 2005-06-23 2005-08-03 Novartis Ag Organic compounds
TWI648281B (zh) 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 含硫二環式化合物
JP2018199623A (ja) 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139240A1 (en) 2006-05-25 2007-12-06 Korea Research Institute Of Chemical Technology 7-(3,4-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidine compounds, process for preparing thereof, and pharmaceutical composition for treating or preventing asthma, chronic obstructive pulmonary disease, arthritis, atopic dermatitis, tumor and degenerative brain diseases comprising the same
JP2011517458A (ja) 2008-03-31 2011-06-09 武田薬品工業株式会社 アポトーシスシグナル調節キナーゼ1阻害剤
US20160304527A1 (en) 2015-04-20 2016-10-20 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use

Also Published As

Publication number Publication date
EP3596080A1 (en) 2020-01-22
SI3596080T1 (sl) 2022-01-31
AR111176A1 (es) 2019-06-12
PL3596080T3 (pl) 2022-01-31
MY195262A (en) 2023-01-11
EP3596080B1 (en) 2021-09-01
CA3056185A1 (en) 2018-09-20
WO2018167630A1 (en) 2018-09-20
HU231058B1 (hu) 2020-04-28
KR20190127779A (ko) 2019-11-13
SG11201907864YA (en) 2019-09-27
HRP20211850T1 (hr) 2022-03-04
ECSP19072975A (es) 2019-11-30
CY1124708T1 (el) 2022-07-22
PH12019501968A1 (en) 2020-06-29
EA038756B1 (ru) 2021-10-14
GEP20217256B (en) 2021-05-25
US11026946B2 (en) 2021-06-08
JP2020510041A (ja) 2020-04-02
CO2019010120A2 (es) 2019-10-09
AU2018235266B2 (en) 2021-09-30
CL2019002601A1 (es) 2020-01-24
UA124783C2 (uk) 2021-11-17
AU2018235266A1 (en) 2019-10-17
US20200129515A1 (en) 2020-04-30
CN110431142A (zh) 2019-11-08
LT3596080T (lt) 2021-11-25
MX2019011000A (es) 2019-10-17
DK3596080T3 (da) 2021-11-15
ES2893824T3 (es) 2022-02-10
HUP1700108A2 (en) 2018-09-28
RS62533B1 (sr) 2021-11-30
PE20191646A1 (es) 2019-11-07
EA201992127A1 (ru) 2020-02-06
BR112019018843A2 (pt) 2020-04-14
HUE056562T2 (hu) 2022-02-28
PT3596080T (pt) 2021-10-22
IL268923A (en) 2019-10-31

Similar Documents

Publication Publication Date Title
JP7153662B2 (ja) 薬理学的に活性な脂環式置換ピラゾロ[1,5-a]ピリミジン誘導体
JP5707390B2 (ja) 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体の正のアロステリック調節因子としてのその使用
JP7153661B2 (ja) 薬理学的に活性なアリール置換ピラゾロ[1,5-a]ピリミジン誘導体
KR20110106450A (ko) 바이시클릭 피라졸로-헤테로사이클
CN121127471A (zh) 作为nlrp3抑制剂的吡唑并嘧啶衍生物
US12473293B2 (en) Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives
JP7013446B2 (ja) Gaba(a)受容体モジュレーター、及び、喘息における気道過敏及び炎症を抑制するための方法
JP2001512124A (ja) 新規な2,3−ベンゾジアゼピン誘導体
EA049144B1 (ru) ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ ЗАМЕЩЕННЫЕ ПО ГЕТЕРОЦИКЛИЧЕСКОМУ ФРАГМЕНТУ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА
OA19480A (en) Pharmacologically active alicyclicsubstituted pyrazolo [1,5-a] pyrimidine derivatives.
EP4384511A1 (en) Fused ring heteroaryl compounds and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220913

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221003

R150 Certificate of patent or registration of utility model

Ref document number: 7153662

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250